ATE469161T1 - Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung - Google Patents
Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellungInfo
- Publication number
- ATE469161T1 ATE469161T1 AT03784564T AT03784564T ATE469161T1 AT E469161 T1 ATE469161 T1 AT E469161T1 AT 03784564 T AT03784564 T AT 03784564T AT 03784564 T AT03784564 T AT 03784564T AT E469161 T1 ATE469161 T1 AT E469161T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- group etc
- alkyl group
- chem
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002232074 | 2002-08-08 | ||
JP2002321729 | 2002-11-05 | ||
PCT/JP2003/010048 WO2004014932A1 (ja) | 2002-08-08 | 2003-08-07 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE469161T1 true ATE469161T1 (de) | 2010-06-15 |
Family
ID=31719857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03784564T ATE469161T1 (de) | 2002-08-08 | 2003-08-07 | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
Country Status (19)
Country | Link |
---|---|
US (2) | US7375087B2 (de) |
EP (1) | EP1544208B1 (de) |
JP (1) | JP4540475B2 (de) |
KR (1) | KR100985502B1 (de) |
AT (1) | ATE469161T1 (de) |
AU (1) | AU2003254847B2 (de) |
BR (1) | BRPI0313290B1 (de) |
CA (1) | CA2494179C (de) |
DE (1) | DE60332743D1 (de) |
ES (1) | ES2345250T3 (de) |
HK (1) | HK1082743A1 (de) |
IL (1) | IL166748A0 (de) |
MX (1) | MXPA05001549A (de) |
NO (1) | NO330456B1 (de) |
NZ (1) | NZ538117A (de) |
PL (1) | PL213095B1 (de) |
RU (1) | RU2356906C2 (de) |
TW (1) | TW200413401A (de) |
WO (1) | WO2004014932A1 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000025598A1 (en) | 1998-11-03 | 2000-05-11 | Dandy A/S | Sucrose fatty acid esters for use as increased release of active ingredients |
JP4540475B2 (ja) * | 2002-08-08 | 2010-09-08 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
JP4606876B2 (ja) * | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
KR20050089156A (ko) * | 2002-12-04 | 2005-09-07 | 깃세이 야쿠힌 고교 가부시키가이샤 | 고혈당증에 기인하는 질환의 예방 또는 치료제 |
WO2004058790A1 (ja) * | 2002-12-25 | 2004-07-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
EP1813611B1 (de) * | 2004-11-18 | 2014-10-01 | Kissei Pharmaceutical Co., Ltd. | 1-substituierte 3-beta-d-glycopyranosylierte stickstoffhaltige heterocyclische verbindungen und medikamente, die diese enthalten |
US7887824B2 (en) | 2004-11-30 | 2011-02-15 | L'oreal | Sulfamide derivatives and cosmetic use thereof |
FR2878523B1 (fr) * | 2004-11-30 | 2007-09-14 | Oreal | Nouveaux derives sulfamides et leur utilisation cosmetique |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
JP4888840B2 (ja) * | 2005-07-22 | 2012-02-29 | 味の素株式会社 | ピラゾール−o−グリコシド誘導体の調製方法及び前記方法の新規中間体 |
UY30082A1 (es) | 2006-01-11 | 2007-08-31 | Boehringer Ingelheim Int | Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos |
JP2009167103A (ja) * | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | ピラゾリル5−チオグリコシド化合物 |
PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
NZ573687A (en) | 2006-05-19 | 2010-10-29 | Taisho Pharmaceutical Co Ltd | C-phenyl glycitol compound for the treatment of diabetes |
WO2007140191A2 (en) | 2006-05-23 | 2007-12-06 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
KR20090023570A (ko) | 2006-06-29 | 2009-03-05 | 다이쇼 세이야꾸 가부시끼가이샤 | C-페닐 1-티오글루시톨 화합물 |
EP2103607A4 (de) | 2006-12-14 | 2011-01-05 | Taisho Pharmaceutical Co Ltd | 1-phenyl-1-thio-d-glucitolderivat |
KR101506935B1 (ko) | 2007-04-02 | 2015-03-31 | 테라코스, 인코포레이티드 | 벤질릭 글리코시드 유도체 및 사용 방법 |
CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
KR101107425B1 (ko) | 2007-08-23 | 2012-01-19 | 테라코스, 인코포레이티드 | 벤질벤젠 유도체 및 사용 방법 |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
RU2482122C2 (ru) * | 2007-12-27 | 2013-05-20 | Киссеи Фармасьютикал Ко., Лтд. | Моносебацинат производного пиразола |
US8283454B2 (en) | 2008-08-22 | 2012-10-09 | Theracos, Inc. | Processes for the preparation of SGLT2 inhibitors |
KR101446454B1 (ko) * | 2008-08-28 | 2014-10-06 | 화이자 인코포레이티드 | 다이옥사-바이사이클로[3.2.1]옥테인-2,3,4-트라이올 유도체 |
US20110046076A1 (en) | 2009-02-13 | 2011-02-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2010216634B2 (en) | 2009-02-23 | 2014-07-10 | Taisho Pharmaceutical Co., Ltd. | 4 -isopropylphenyl glucitol compounds as SGLT1 inhibitors |
EP2298782A1 (de) * | 2009-08-26 | 2011-03-23 | Sanofi-Aventis | Verfahren zur Herstellung von Pyrazol-glykosid-Derivate |
US8147801B2 (en) | 2009-09-15 | 2012-04-03 | Janssen Pharmaceutica, N.V. | Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion |
EA022032B1 (ru) * | 2009-09-30 | 2015-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения глюкопиранозилзамещенных производных бензилбензола |
MX2012002942A (es) * | 2009-09-30 | 2012-04-11 | Boehringer Ingelheim Int | Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno. |
UY32919A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
CN102753184A (zh) * | 2009-10-02 | 2012-10-24 | 赛诺菲 | 具有sglt-1/sglt-2抑制剂活性的化合物在制备用于治疗骨病的药物中的用途 |
JP5696156B2 (ja) | 2009-11-02 | 2015-04-08 | ファイザー・インク | ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
JP6042330B2 (ja) | 2010-07-09 | 2016-12-14 | ビーエイチヴィ ファーマ、インコーポレイテッド | レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時/遅延放出送達システム |
JP2013224263A (ja) * | 2010-08-19 | 2013-10-31 | Taisho Pharmaceutical Co Ltd | 4−イソプロピルフェニルグルシトール化合物 |
US9161945B2 (en) | 2010-08-20 | 2015-10-20 | Taisho Pharmaceutical Co., Ltd. | 4-isopropyl-6-methoxyphenyl glucitol compound |
CN103168035B (zh) * | 2010-08-20 | 2016-01-20 | 大正制药株式会社 | 4-异丙基苯基山梨醇化合物的晶型及其制备方法 |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2012176804A1 (ja) * | 2011-06-20 | 2012-12-27 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体 |
SG195100A1 (en) | 2011-07-01 | 2013-12-30 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
TW201425326A (zh) * | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
SG11201506047PA (en) | 2013-02-04 | 2015-09-29 | Taisho Pharmaceutical Co Ltd | Prophylactic or therapeutic drug for constipation |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2021004308A (es) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria. |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
AR098670A1 (es) | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
CN110054657B (zh) * | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | 吡喃葡萄糖取代的吡唑化合物及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1083335A (en) * | 1976-05-10 | 1980-08-12 | Chemed Corporation | Composition and method of inhibiting corrosion |
US5274111A (en) * | 1992-04-07 | 1993-12-28 | American Home Products Corporation | Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof |
EP1022028A1 (de) | 1997-08-27 | 2000-07-26 | Takeda Chemical Industries, Ltd. | Orale zubereitung mit verlängerter freigabe |
WO1999026606A2 (en) | 1997-11-25 | 1999-06-03 | Bayer Aktiengesellschaft | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS |
MXPA01010109A (es) * | 1999-04-06 | 2002-06-04 | Sankyo Co | Derivados de acido carboxilico alfasustituidos. |
JP2001002567A (ja) | 1999-04-20 | 2001-01-09 | Takeda Chem Ind Ltd | 水溶性薬物を含有する徐放性製剤 |
RU2232767C2 (ru) | 1999-08-31 | 2004-07-20 | Киссеи Фармасьютикал Ко., Лтд. | Глюкопиранозилоксипиразольные производные, фармацевтические композиции, содержащие эти производные, и промежуточные соединения для их получения |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
DE60141156D1 (de) * | 2000-11-02 | 2010-03-11 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
DE60138768D1 (de) * | 2000-12-28 | 2009-07-02 | Kissei Pharmaceutical | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
JP4540475B2 (ja) * | 2002-08-08 | 2010-09-08 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
EP1550668A4 (de) * | 2002-10-04 | 2008-10-01 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt für dessen herstellung |
JP4285338B2 (ja) * | 2004-06-14 | 2009-06-24 | トヨタ自動車株式会社 | スターリングエンジン |
-
2003
- 2003-08-07 JP JP2004527355A patent/JP4540475B2/ja not_active Expired - Fee Related
- 2003-08-07 RU RU2005106259/04A patent/RU2356906C2/ru not_active IP Right Cessation
- 2003-08-07 ES ES03784564T patent/ES2345250T3/es not_active Expired - Lifetime
- 2003-08-07 KR KR1020057002286A patent/KR100985502B1/ko not_active IP Right Cessation
- 2003-08-07 BR BRPI0313290A patent/BRPI0313290B1/pt not_active IP Right Cessation
- 2003-08-07 MX MXPA05001549A patent/MXPA05001549A/es active IP Right Grant
- 2003-08-07 DE DE60332743T patent/DE60332743D1/de not_active Expired - Lifetime
- 2003-08-07 NZ NZ538117A patent/NZ538117A/en not_active IP Right Cessation
- 2003-08-07 EP EP03784564A patent/EP1544208B1/de not_active Expired - Lifetime
- 2003-08-07 AT AT03784564T patent/ATE469161T1/de not_active IP Right Cessation
- 2003-08-07 PL PL375473A patent/PL213095B1/pl unknown
- 2003-08-07 US US10/523,820 patent/US7375087B2/en not_active Expired - Fee Related
- 2003-08-07 AU AU2003254847A patent/AU2003254847B2/en not_active Ceased
- 2003-08-07 WO PCT/JP2003/010048 patent/WO2004014932A1/ja active Application Filing
- 2003-08-07 CA CA2494179A patent/CA2494179C/en not_active Expired - Fee Related
- 2003-08-08 TW TW092121803A patent/TW200413401A/zh not_active IP Right Cessation
-
2005
- 2005-02-08 IL IL16674805A patent/IL166748A0/xx active IP Right Grant
- 2005-03-08 NO NO20051209A patent/NO330456B1/no not_active IP Right Cessation
-
2006
- 2006-02-27 HK HK06102572A patent/HK1082743A1/xx not_active IP Right Cessation
-
2008
- 2008-04-17 US US12/104,890 patent/US7655632B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60332743D1 (de) | 2010-07-08 |
PL213095B1 (pl) | 2013-01-31 |
NO330456B1 (no) | 2011-04-18 |
BR0313290A (pt) | 2005-07-05 |
CA2494179A1 (en) | 2004-02-19 |
BRPI0313290B1 (pt) | 2016-12-06 |
TWI341843B (de) | 2011-05-11 |
KR20050059067A (ko) | 2005-06-17 |
MXPA05001549A (es) | 2005-05-05 |
PL375473A1 (en) | 2005-11-28 |
JP4540475B2 (ja) | 2010-09-08 |
EP1544208A1 (de) | 2005-06-22 |
EP1544208B1 (de) | 2010-05-26 |
US7375087B2 (en) | 2008-05-20 |
RU2005106259A (ru) | 2005-08-27 |
US7655632B2 (en) | 2010-02-02 |
KR100985502B1 (ko) | 2010-10-05 |
AU2003254847B2 (en) | 2009-06-04 |
NO20051209L (no) | 2005-04-15 |
CA2494179C (en) | 2012-04-24 |
IL166748A0 (en) | 2006-01-15 |
AU2003254847A1 (en) | 2004-02-25 |
EP1544208A4 (de) | 2007-05-02 |
US20060166899A1 (en) | 2006-07-27 |
RU2356906C2 (ru) | 2009-05-27 |
TW200413401A (en) | 2004-08-01 |
ES2345250T3 (es) | 2010-09-20 |
NZ538117A (en) | 2007-01-26 |
WO2004014932A1 (ja) | 2004-02-19 |
HK1082743A1 (en) | 2006-06-16 |
JPWO2004014932A1 (ja) | 2005-12-02 |
US20080312153A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE469161T1 (de) | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung | |
ATE557030T1 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
ATE264337T1 (de) | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung | |
ATE312114T1 (de) | Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate | |
WO2002044192A1 (fr) | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions | |
ATE541854T1 (de) | Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung | |
WO2003011880A1 (fr) | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition | |
NZ545692A (en) | PPAR-activating compound and pharmaceutical composition containing same | |
MXPA03002779A (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos. | |
TW200745070A (en) | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and their use | |
EP1400529A4 (de) | Glucopyranosyloxypyrazol derivat, diese enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt zu dessen herstellung | |
WO2002055496A8 (en) | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | |
NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
AU9233101A (en) | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | |
DE602004019778D1 (de) | Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen | |
MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
IL169577A0 (en) | Oligosaccharide derivatives and pharmaceutical compostions containing the same | |
TW200511990A (en) | Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |